What are the treatment options for steatosis (fatty liver disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Treating fatty liver primarily involves lifestyle modifications, with a focus on weight loss, dietary changes, and regular exercise, as recommended by the most recent guidelines 1.

Key Recommendations

  • Lifestyle modification is the cornerstone of treatment, aiming for a gradual 5-10% reduction in body weight through a balanced diet and regular exercise 1.
  • Limit alcohol consumption completely or significantly, as alcohol worsens liver damage.
  • Follow a Mediterranean-style diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while avoiding processed foods, sugary beverages, and high-fructose corn syrup.
  • Exercise regularly with at least 150 minutes of moderate activity weekly.
  • Control diabetes and high cholesterol if present, as these conditions can worsen fatty liver.

Medications and Other Interventions

  • Currently, no medications are specifically FDA-approved for fatty liver treatment, though vitamin E (800 IU daily) may help in non-diabetic patients with confirmed NASH 1.
  • Pioglitazone and GLP-1 RAs, such as semaglutide, may be beneficial in improving glucose and lipid metabolism, reversing steatohepatitis, and improving fibrosis in people with type 2 diabetes and NASH 1.
  • Bariatric surgery may be an option in individuals with fatty liver disease and obesity 1.

Monitoring and Follow-up

  • Regular follow-up with healthcare providers is essential to monitor liver function and adjust treatment as needed.
  • Non-invasive tests, such as blood-based scores and imaging techniques, can be used to rule out advanced fibrosis and monitor disease progression 1.

From the Research

Treatment Options for Fatty Liver

  • Lifestyle intervention is an effective treatment for non-alcoholic fatty liver disease (NAFLD) patients, as it can decrease cardiovascular and diabetes risk and regress liver disease 2.
  • Weight loss is a crucial aspect of treating NAFLD, with weight reductions of ≥10% inducing a near-universal non-alcoholic steatohepatitis resolution and fibrosis improvement by at least one stage 2, 3.
  • Modest weight loss (>5%) can also produce important benefits on the components of the NAFLD activity score (NAS) 2.
  • The Mediterranean diet is recommended for NAFLD patients, as it can reduce liver fat even without weight loss, and is characterized by reduced carbohydrate intake and increased monounsaturated and omega-3 fatty acid intake 2.

Dietary Modifications

  • The habitual diet plays a relevant role in the pathogenesis of NAFLD, with risky foods (e.g., fructose) and protective foods (e.g., Mediterranean diet) described 3.
  • Excess calories remain a pivotal contributor to fatty liver accumulation, and weight loss is the most effective way to promote liver fat removal 3.
  • A holistic, multidisciplinary, and individualized approach to disease management is key to achieving population-level change in NAFLD treatment 4.

Pharmacological Treatments

  • There are no approved pharmacological treatments for NASH/NAFLD, but several clinical trials have been undertaken to evaluate the efficacy of various agents 5.
  • Pioglitazone is the only agent that has shown consistent benefit and efficacy in clinical trials, while other agents such as pentoxifylline, rosiglitazone, and ursodeoxycholic acid have had mixed results 5.
  • Vitamin E and metformin have also shown evidence of efficacy in treating NAFLD/NASH 5, 6.

Management and Prevention

  • Lifestyle modification is the foundation of treatment for patients with non-alcoholic steatosis, and early identification of patients with non-alcoholic steatohepatitis may help improve patient outcomes through treatment intervention 6.
  • The association between non-alcoholic steatohepatitis and cardiovascular disease is clear, and the incidence of non-alcoholic fatty liver disease-related hepatocellular carcinoma is increasing 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.